Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760845 | 1.00 | JAK2 (0.39) | JAK2LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5762505 | 0.99 | JAK2 (0.38) | JAK2LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5762502 | 0.99 | JAK2 (0.38) | JAK2LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5760513 | 0.84 | JAK2 (0.40) | JAK2LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5760519 | 0.84 | JAK2 (0.40) | JAK2LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5762955 | 0.84 | BRD4 (0.34) | JAK2LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5763089 | 0.84 | BRD4 (0.34) | JAK2LMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5760808 | 0.82 | JAK2 (0.38) | JAK2 | |
| SCHEMBL5760804 | 0.82 | JAK2 (0.38) | JAK2 | |
| SCHEMBL5761530 | 0.82 | JAK2 (0.38) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458683-B1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7012077-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1458683-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003053933-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186984-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | JAK2 3542/4885LMNA 794/4885CHRM2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.